Yıldırım, Ali Osman

Profile Picture
Name Variants
A. Osman Yıldırım
A. O. Yildirim
Ali O. Yildirim
Yıldırım, Ali Osman
Yildirim A.
Ali Osman Yildirim
Yıldırım, Osman
A. O. YiLDiRiM
Yıldırım Ali Osman
Ali Osman, Yıldırım
Ali Osman YILDIRIM
Yildirim, Osman
Yildirim, A.
Ali Osman YiLDiRiM
Yıldırım, A.
Yıldırım, O.
Yildirim Ali Osman
Yildirim, O.
Yildirim, Ali
Ali O. Yıldırım
A. O. Yıldırım
A. O. YILDIRIM
YiLDiRiM Ali Osman
Yıldırım, Ali
Ali Osman Yıldırım
YILDIRIM Ali Osman
A. Osman Yildirim
Osman Yıldırım
Osman Yıldırım
Job Title
Prof.Dr.
Email Address
osman.yildirim@okan.edu.tr
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Scholarly Output

4

Articles

4

Citation Count

0

Supervised Theses

0

Filters

2019 - 201912020 - 20233
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Article
    Citation Count: 0
    Oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer
    (Polish Urological Assoc, 2023) Sendogan, Furkan; Turan, Turgay; Keser, Ferhat; Hancilar, Tayfun; Atis, Gokhan; Yildirim, Asif; Acil Tıp / Emergency Medicine
    Introduction The aim of this study was to compare the long-term oncological results of patients with the diagnosis of prostate cancer who underwent open radical retropubic prostatectomy (RRP) and subse-quent adjuvant (ART) or salvage radiotherapy (SRT).Material and methods A total of 145 patients underwent open RRP for prostate cancer and subsequent ART or SRT postoperatively between 2010 and 2019. ART (n = 56) is defined as the group of patients with prostate-specific antigen (PSA) <0.2 ng/mL or with positive lymph nodes without PSA increase who re-ceived radiotherapy within the first 6 months of urinary continence. SRT (n = 89) is defined as the group of patients with PSA >0.2 ng/mL who received RT before PSA amounted to 0.5 ng/mL.Results Statistically no significant difference was found between groups in terms of age, prostate volume, final pathology Gleason scores, lymphadenectomy, duration of androgen deprivation therapy (ADT), time to relapse after radiotherapy, development of biochemical recurrence and disease progression. Extraprostatic extension, seminal vesicle invasion and surgical margin positivity were significantly higher in the ART group. No difference was found between the groups in terms of biochemical recurrence-free survival, while cancer-specific survival and overall survival rates were significantly higher in the SRT group.Conclusions It was found that cancer-specific and overall survival was better in the SRT group. It will be more appropriate to follow-up until the recurrence and then to perform SRT after the relapse in the postoperative period.
  • Thumbnail Image
    Article
    Citation Count: 0
    An unusual cause of hemorrhagic shock: gastric Dieulafoy’s lesion
    (2019) Ahmet Erdoğan; Osman Yıldırım; Murat Ferhat Ferhatoğlu; Hikmet Pehlevan; Kazım Şenol; Acil Tıp / Emergency Medicine
    Dieulafoy's lesion (DL) related massive gastrointestinal bleeding is a rare and mortal health condition. DL isa superficial vascular lesion of the gastric mucose that is mostly located in the proximal part of the stomachwhich is difficult to diagnose. Endoscopy is a safe and effective method for diagnosis and treatment. However,emergency surgery should be essential for diagnosis and treatment. Here we present a succesfull clinical andsurgical management of a case with massive gastrointestinal bleeding related to gastric DL.
  • Thumbnail Image
    Article
    Citation Count: 4
    Aberrant socs3 promoter methylation as a noninvasive diagnostic biomarker for locally advanced prostate cancer;
    (Logos Medical Publishing, 2020) Demircan Tan,B.; Turan,T.; Yucel,B.; Altundag Kara,S.; Salman Yilmaz,S.; Yildirim,A.; Acil Tıp / Emergency Medicine
    Objective: The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, bloodbased epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa). Method: A total of 41 consecutive patients and 10 healthy control groups were enrolled in the study. Pyrosequencing was performed to analyze the methylation levels of the promoter regions of the four tumor suppressor genes in patients compared to healthy controls. Results: The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differ between the patient and control groups. However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localized PCa (p<0.05). Conclusion: Our results indicated that SOCS3 could be a useful, noninvasive blood-based epigenetic biomarker for the diagnosis of locally advanced PCa. © Istanbul Medeniyet University Faculty of Medicine.
  • Thumbnail Image
    Article
    Citation Count: 5
    Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer
    (Wolters Kluwer Medknow Publications, 2021) Culpan,M.; Turan,T.; Ozkanli,S.; Zenginkinet,T.; Kazan,O.; Ucar,T.; Yildirim,A.; Acil Tıp / Emergency Medicine
    Purpose: To investigate the prognostic and clinicopathologic value of Ki-67 and profilin 1 immunohistochemical expression in primary pT1 papillary urothelial bladder cancer. Materials and Methods: This study included 88 male and 13 female pT1 primary bladder cancer patients. Demographic characteristics, tumor histological grade, tumor number, presence of concomitant carcinoma in situ, tumor size, and status of recurrence or progression were recorded for each patient. Expression of Ki-67 and profilin 1 was evaluated by immunohistochemical analysis of paraffin-embedded tumor tissues. The Pearson's Chi-square test was used for the analysis of qualitative data, and the Kaplan-Meier method and the log-rank test were used for the survival analysis. Results: In the mean follow-up period of 52 months, 52 (51.5%) patients experienced recurrence, 24 (23.8%) patients experienced progression, and 17 (16.8%) patients died from bladder cancer-related causes. Ki-67 expression was significantly associated with tumor histological grade (P = 0.001). In multivariate analysis, Ki-67 positivity had significantly worse outcome for recurrence (P = 0.006) and mortality (P = 0.022). Ki-67-positive (Ki-67 index =15%) patients had shorter recurrence-free (P = 0.003), progression-free (P = 0.002), and cancer-specific (P = 0.003) survival. However, no statistically significant relationship was found between profilin 1 expression and clinicopathologic features and prognosis. Conclusions: Ki-67 is a highly predictive biomarker for recurrence-free, progression-free, and cancer-specific survival in pT1 bladder cancer patients, in whom prediction of recurrence and progression are difficult. Ki-67 expression can be safely combined with other prognostic factors. However, in pT1 bladder cancer patients, no significant relationship was found between profilin 1 expression and tumor characteristics or prognostic parameters. © 2021 Journal of Cancer Research and Therapeutics | Published by Wolters Kluwer-Medknow.